🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

CARES : Customized Aftercare Report for Evaluated Skin Cancer Patients

RecruitingNAAges 18 Years - 80 YearsAllUniversitaire Ziekenhuizen KU Leuven
NCT07330323 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Current clinical practices often provide general verbal advice to low-risk patients, which may not sufficiently address individual concerns or offer actionable steps. Generic information on the internet can be overwhelming or unreliable, leading to confusion and unnecessary follow-up visits. This project introduces a tailored approach by combining evidence-based guidelines with personalized details about the patient's risk profile. The discharge letter bridges the gap between clinical expertise and patient understanding, offering clear, specific, and actionable advice that has been shown to improve health behaviors and outcomes in other contexts . The personalized discharge letters are generated using an AI agent trained on validated letters from the hospital's electronic health record system (KWS). Each letter is reviewed and approved by a physician before being provided to the patien

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures * Low-risk skin cancer patients: 1. Negative personal history for melanoma 2. Less than 100 naevi 3. Less than 5 clinically atypical naevi 4. Maximum 1 BCC in history 5. Maximum 1 SCC, and at least 5 years ago 6. AK: treated and controlled with clinical response 7. M Bowen: treated and controlled with clinical response * Adult subjects (between 18 years of age and 80 years) at time of enrolment Exclusion Criteria: * Presence of dermatological lesions requiring immediate treatment at the time of consultation. * History of solid organ transplantation (Organ Transplant Recipient, OTR). * Known carriers or suspected carriers (based on family history) of germline mutations associated with increased skin cancer risk (e.g. CDKN2A, PTCH1, XP genes). * Failure to meet one or more of the inclusion criteria. * Any condition or comorbidity that, in the opinion of the investigator, may interfere with study participation or data interpretation (e.g. severe cognitive impairment, language barrier). * Participation in another interventional clinical trial that may interfere with the outcomes of this study.
💊

What it tests

  • Verbal information only
  • Personalized Discharge Letter
  • Personalized Discharge Letter + IntelliStudio
📍

Where

1 site
UZLeuven, Department of Dermatology
Leuven, Belgium
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy